journal article·2018-11-05Open access

Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38

Mona Alibolandi, Sara Amel Farzad, Marzieh Mohammadi, Khalil Abnous, Seyed Mohammad Taghdisi, Fatemeh Kalalinia, Mohammad Ramezani

Abstract

New integrin-targeted nanoparticles made of chitosan-stabilized PLGA matrix was developed to specifically target colon adenocarcinoma. To this aim, SN38-encapsulated chitosan-coated PLGA NPs were conjugated with tetrac for integrin receptor-guided delivery. To provide a sustained release pattern for SN38, it was loaded into nanoparticles using single emulsion method. The size of NPs were 174.23 ± 6.12 nm with drug encapsulation efficiency and loading content of 73.16 ± 11.15 and 4.45 ± 0.31, respectively. The in vitro results confirmed that the designed nanoplatform showed specific cellular uptake and cytotoxicity in integrin overexpressing cancer cells and provided a sustained release profile for SN38. Additionally, an increased therapeutic potency of targeted formulation over both non-targeted and free drug was shown in vivo.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;

Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Funding

Mashhad University of Medical Sciences

References (31)

Show source-provided references
1. 10.1016/j.ijpharm.2017.09.03910.1016/j.ijpharm.2017.09.039 ↗
2. 10.1021/acsami.7b0821810.1021/acsami.7b08218 ↗
3. 10.1021/mp500254j10.1021/mp500254j ↗
4. 10.1161/01.RES.0000130784.90237.4a10.1161/01.RES.0000130784.90237.4a ↗
5. 10.1016/j.jconrel.2017.08.03010.1016/j.jconrel.2017.08.030 ↗
6. 10.1016/j.ijpharm.2017.01.04410.1016/j.ijpharm.2017.01.044 ↗
7. 10.1016/j.ejpb.2018.01.00710.1016/j.ejpb.2018.01.007 ↗
8. 10.1016/j.addr.2017.12.01510.1016/j.addr.2017.12.015 ↗
9. 10.1016/j.canlet.2017.04.00810.1016/j.canlet.2017.04.008 ↗
10. 10.1038/s41598-017-15012-510.1038/s41598-017-15012-5 ↗
11. 10.1016/j.jconrel.2016.09.01210.1016/j.jconrel.2016.09.012 ↗
12. 10.1016/j.jconrel.2017.10.03710.1016/j.jconrel.2017.10.037 ↗
13. 10.1016/j.carbpol.2016.12.00910.1016/j.carbpol.2016.12.009 ↗
14. 10.1021/acsami.7b1002710.1021/acsami.7b10027 ↗
15. 10.1021/mp050032z10.1021/mp050032z ↗
16. 10.1007/978-1-60761-416-6_2110.1007/978-1-60761-416-6_21 ↗
17. 10.1080/21691401.2018.144696910.1080/21691401.2018.1446969 ↗
18. 10.3109/21691401.2015.110523910.3109/21691401.2015.1105239 ↗
19. 10.1016/j.carbpol.2018.03.10210.1016/j.carbpol.2018.03.102 ↗
20. 10.1007/s12272-013-0276-210.1007/s12272-013-0276-2 ↗
21. 10.2217/nnm.12.20010.2217/nnm.12.200 ↗
22. Davis PJ · Front Endocrinol · 2014 · 5 · 240
23. 10.1007/s12672-017-0293-610.1007/s12672-017-0293-6 ↗
24. 10.1007/s12672-014-0204-z10.1007/s12672-014-0204-z ↗
25. 10.1016/j.exer.2011.11.00310.1016/j.exer.2011.11.003 ↗
26. 10.1016/j.jconrel.2015.04.02610.1016/j.jconrel.2015.04.026 ↗
27. 10.2147/IJN.S12374210.2147/IJN.S123742 ↗
28. 10.1080/21691401.2016.117813010.1080/21691401.2016.1178130 ↗
29. Li F · Am J Cancer Res · 2017 · 7 · 2350
30. 10.1080/21691401.2017.142213010.1080/21691401.2017.1422130 ↗
31. Davis PJ · BioMed Res Int. · 2015 · 168427